We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Epstein-Barr virus–positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma.
- Authors
Tse, Eric; Au-Yeung, Rex; Chau, David; Hwang, Yu-Yan; Loong, Florence; Kwong, Yok-Lam
- Abstract
Epstein-Barr virus-positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma Right axillary lymph node biopsy showed mixed cellularity classical Hodgkin lymphoma (cHL) (Fig. 1 Mixed cellularity classical Hodgkin lymphoma treated with frontline brentuximab vedotin, and subsequent development of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma, polymorphic type. Cervical lymph node biopsy showed Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL), polymorphic pattern [[4]], non-germinal centre B-cell (non-GCB, Hans algorithm) in origin immunohistochemically (Fig.
- Subjects
HODGKIN'S disease; DIFFUSE large B-cell lymphomas; B cell lymphoma; PROGNOSIS; PROGRESSIVE multifocal leukoencephalopathy; THERAPEUTICS
- Publication
Annals of Hematology, 2022, Vol 101, Issue 5, p1149
- ISSN
0939-5555
- Publication type
Letter
- DOI
10.1007/s00277-021-04709-3